267 related articles for article (PubMed ID: 28326839)
1. Entinostat: a promising treatment option for patients with advanced breast cancer.
Connolly RM; Rudek MA; Piekarz R
Future Oncol; 2017 Jun; 13(13):1137-1148. PubMed ID: 28326839
[TBL] [Abstract][Full Text] [Related]
2. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
Connolly RM; Zhao F; Miller KD; Lee MJ; Piekarz RL; Smith KL; Brown-Glaberman UA; Winn JS; Faller BA; Onitilo AA; Burkard ME; Budd GT; Levine EG; Royce ME; Kaufman PA; Thomas A; Trepel JB; Wolff AC; Sparano JA
J Clin Oncol; 2021 Oct; 39(28):3171-3181. PubMed ID: 34357781
[TBL] [Abstract][Full Text] [Related]
3. Entinostat for the treatment of breast cancer.
Trapani D; Esposito A; Criscitiello C; Mazzarella L; Locatelli M; Minchella I; Minucci S; Curigliano G
Expert Opin Investig Drugs; 2017 Aug; 26(8):965-971. PubMed ID: 28718331
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
Yardley DA; Ismail-Khan RR; Melichar B; Lichinitser M; Munster PN; Klein PM; Cruickshank S; Miller KD; Lee MJ; Trepel JB
J Clin Oncol; 2013 Jun; 31(17):2128-35. PubMed ID: 23650416
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer.
Masuda N; Tamura K; Yasojima H; Shimomura A; Sawaki M; Lee MJ; Yuno A; Trepel J; Kimura R; Nishimura Y; Saji S; Iwata H
BMC Cancer; 2021 Nov; 21(1):1269. PubMed ID: 34819039
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
Ngamphaiboon N; Dy GK; Ma WW; Zhao Y; Reungwetwattana T; DePaolo D; Ding Y; Brady W; Fetterly G; Adjei AA
Invest New Drugs; 2015 Feb; 33(1):225-32. PubMed ID: 25371323
[TBL] [Abstract][Full Text] [Related]
7. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
8. Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer.
Wang J; Zhang Q; Li Q; Mu Y; Jing J; Li H; Li W; Wang J; Yu G; Wang X; Ouyang Q; Hao J; Lu L; Zhou L; Guan J; Li Q; Xu B
Target Oncol; 2021 Sep; 16(5):591-599. PubMed ID: 34196874
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.
Pili R; Salumbides B; Zhao M; Altiok S; Qian D; Zwiebel J; Carducci MA; Rudek MA
Br J Cancer; 2012 Jan; 106(1):77-84. PubMed ID: 22134508
[TBL] [Abstract][Full Text] [Related]
10. Entinostat plus exemestane has activity in ER+ advanced breast cancer.
Cancer Discov; 2013 Jul; 3(7):OF17. PubMed ID: 23847360
[TBL] [Abstract][Full Text] [Related]
11. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.
Connolly RM; Li H; Jankowitz RC; Zhang Z; Rudek MA; Jeter SC; Slater SA; Powers P; Wolff AC; Fetting JH; Brufsky A; Piekarz R; Ahuja N; Laird PW; Shen H; Weisenberger DJ; Cope L; Herman JG; Somlo G; Garcia AA; Jones PA; Baylin SB; Davidson NE; Zahnow CA; Stearns V
Clin Cancer Res; 2017 Jun; 23(11):2691-2701. PubMed ID: 27979916
[No Abstract] [Full Text] [Related]
12. The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines.
Elmer JJ; Christensen MD; Barua S; Lehrman J; Haynes KA; Rege K
Biotechnol Bioeng; 2016 Jun; 113(6):1345-1356. PubMed ID: 26614912
[TBL] [Abstract][Full Text] [Related]
13. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models.
Kurmasheva RT; Bandyopadhyay A; Favours E; Del Pozo V; Ghilu S; Phelps DA; Erickson SW; Peer CJ; Figg WD; Smith MA; Houghton PJ
Pediatr Blood Cancer; 2019 Aug; 66(8):e27820. PubMed ID: 31099166
[TBL] [Abstract][Full Text] [Related]
15. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.
Lim B; Murthy RK; Lee J; Jackson SA; Iwase T; Davis DW; Willey JS; Wu J; Shen Y; Tripathy D; Alvarez R; Ibrahim NK; Brewster AM; Barcenas CH; Brown PH; Giordano SH; Moulder SL; Booser DJ; Moscow JA; Piekarz R; Valero V; Ueno NT
Br J Cancer; 2019 Jun; 120(12):1105-1112. PubMed ID: 31097774
[TBL] [Abstract][Full Text] [Related]
16. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
[TBL] [Abstract][Full Text] [Related]
17. Entinostat (SNDX-275) for the treatment of non-small cell lung cancer.
Ruiz R; Raez LE; Rolfo C
Expert Opin Investig Drugs; 2015; 24(8):1101-9. PubMed ID: 26098363
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Schech AJ; Shah P; Yu S; Sabnis GJ; Goloubeva O; Rosenblatt P; Kazi A; Chumsri S; Brodie A
Breast Cancer Res Treat; 2015 Aug; 152(3):499-508. PubMed ID: 26133921
[TBL] [Abstract][Full Text] [Related]
19. INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies.
van Tilburg CM; Witt R; Heiss M; Pajtler KW; Plass C; Poschke I; Platten M; Harting I; Sedlaczek O; Freitag A; Meyrath D; Taylor L; Balasubramanian GP; Jäger N; Pfaff E; Jones BC; Milde T; Pfister SM; Jones DTW; Kopp-Schneider A; Witt O
BMC Cancer; 2020 Jun; 20(1):523. PubMed ID: 32503469
[TBL] [Abstract][Full Text] [Related]
20. Entinostat for treatment of solid tumors and hematologic malignancies.
Knipstein J; Gore L
Expert Opin Investig Drugs; 2011 Oct; 20(10):1455-67. PubMed ID: 21888556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
